source
- Sarepta's Elevidys sales beat forecasts but dip again, prompting stock slide and shift to RNA pipelineSarepta Therapeutics reported that its gene therapy Elevidys generated net product revenue that exceeded Wall Street estimates for the first quarter. However, sales continued to decline compared wi…
- Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increaseEntrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…